key: cord-0068499-tqgjrh81
authors: Zhang, S.; Robledo, F.; Shrestha, C.; Wisniewski, B.; Brown, N.; Carey, K.; Pham, H.; Partida-Sanchez, S.; Kopp, B.
title: 383: Cystic fibrosis macrophage function after elexacaftor/tezacaftor/ivacaftor initiation
date: 2021-10-15
journal: J Cyst Fibros
DOI: 10.1016/s1569-1993(21)01807-5
sha: c31e5ca98d42df9d45c9fa5d9ec490d16302e278
doc_id: 68499
cord_uid: tqgjrh81

nan

A. Recchiuti 1 , S. Patruno 1 , D. Mattoscio 1 , E. Isopi 1 , A. Pomilio 1 , R. Pecce 1 , M. Romano 1 . 1 Medical, Oral, and Biotechnological Sciences, Università "G. d'Annunzio" Chieti -Pescara, Chieti, Italy Background: In the clinical setting, people with chronic diseases linked to nonresolving inflammation such as cystic fibrosis (CF) are considered at high risk for severe illness from COVID-19 [1] . Resolution of inflammation is an active process in which specialized proresolving lipid mediators such as resolvin (Rv)D1 and RvD2 play pivotal roles in curbing the disproportionate host response while promoting the removal of the noxious stimulus [2, 3] . Therefore, determining pathological responses activated by SARS-CoV-2 in CF and actions of specialized proresolving lipid mediators in SARS-CoV-2induced inflammation are of outmost importance. Methods: Macrophages from volunteers with CF (CF-MΦ) and without CF (non-CF MΦ) were screened for cytokines, chemokines, interferons, growth factors, and microRNAs involved in immune response activated by SARS-CoV-2 spike protein 1 (S1). Bioactivities of RvD1 and RvD2 on these S1triggered cell immune responses and on phagocytosis of Pseudomonas aeruginosa one-way ANOVA or t test were used to compare differences between means (±SE) from each group. Significance was set as P < 0.05. Results: S1 (10 μg/mL, 3 hour) significantly increased the release of chemokines (IL-8, MIP-1α, −1β, MCP-1) by CF MΦ and non-CF MΦ. In contrast, there was a significant increase in IL-6 and TNF-α released by non-CF MΦ but not CF cells and a significantly higher induction of MCP-1 and MIP-1β in non-CF MΦ. IL-8 and MIP-1α steadily increased in a timedependent manner 3 to 24 hours after stimulation with S1 of CF MΦ, whereas they plateaued after 3 hours in non-CF MΦ. TNF-α timedependently increased in CF and non-CF MΦ, whereas IL-6 was enhanced only in non-CF MΦ at 24 hours. Hence, S1 activated a NF-kB-driven, but not interferon-dependent, inflammatory program in CF and non-CF MΦ. After 3 hours of treatment with S1, RvD1 was augmented in CF MΦ, indicating activation of specialized proresolving lipid biosynthetic pathways in these cells but not in non-CF MΦ. RvD1 or RvD2 (10 nM) significantly dampened IL-8, MIP-1α, and TNF-α elicited by S1 in CF and non-CF MΦ by approximately 25% to 50%, whereas they had selective reductive effects on IL-6 in non-CF cells. In CF and non-CF MΦ, RvD1 and RvD2 increased miR-26a and −16 expression, which dampens inflammatory cytokines, whereas miR-223 and miR-125a, which are involved in MΦ activation, were upregulated in a selective manner by RvD1 and RvD2, respectively. RvD1 and RvD2 also enhanced phagocytosis of P. aeruginosa by CF and non-CF MΦ stimulated with S1. Conclusion: These results show the first MΦ responses that are important in COVID-19-related inflammation and resolution, demonstrating that S1 protein has direct, infection-independent, and different proinflammatory actions on CF and non-CF MΦ. The results also foster larger serological and blood cell analyses to assess these differences in CoV-2-positive CF patients and the general population and their impact on clinical manifestations Background: CFTR dysfunction results in multiple abnormalities, including abnormal ion transport and dysregulated host immunity, characterized by poor antimicrobial function and excess inflammation. Macrophages are one such critically altered innate immune cell in CF. Triple combination elexacaftor/tezacaftor/ivacaftor is a new, highly effective CFTR modulator therapy for people with CF (PwCF), with unknown effects on innate immunity. This study aimed to investigate if elexacaftor/tezacaftor/ ivacaftor alters CF macrophage functional responses. Methods: PwCF ( pre-or post-elexacaftor/tezacaftor/ivacaftor treatment) and age-matched non-CF controls were enrolled in a 1-year prospective study. Monocytes were isolated from peripheral blood and analyzed immediately after isolation or differentiated into macrophages (monocytederived macrophages [MDMs]), which were treated with elexacaftor/ tezacaftor/ivacaftor ex vivo (5 mM) 48 hours before experiments. CFTR expression was analyzed by intracellular staining, Western blot, and its distribution was tracked by confocal imaging. CFTR function was measured by halide efflux and whole-cell patch-clamp. Phagocyte function studies were performed using clinical isolates of Burkholderia cenocepacia and Pseudomonas aeruginosa, along with clearance of CFSE-labelled, apoptotic human neutrophils. Interactions were confirmed with scanning or transmission electron microscopy. Results: Elexacaftor/tezacaftor/ivacaftor increased cytosolic and membrane MDM CFTR protein expression, with increased trafficking to the plasma membrane confirmed by confocal microscopy. Increases in CFTR expression corresponded with increased CFTR function as measured by halide efflux and patch-clamp but were variable between individuals and minimal for freshly isolated monocytes. Elexacaftor/tezacaftor/ivacaftor reduced M 2 MDM polarization and antiinflammatory IL-10 production but did not affect proinflammatory cytokine production despite also reducing M 1 polarization. Elexacaftor/tezacaftor/ivacaftor improved neutrophil efferocytosis, bacterial phagocytosis, intracellular reactive oxygen species production, and bacterial killing but did not fully resolve levels of these functions compared to non-CF. Scanning or transmission electron microscopy demonstrated persisting morphologic changes in CF MDMs after elexacaftor/tezacaftor/ivacaftor associated with abnormalities in cytoskeletal genes. Conclusion: Overall, elexacaftor/tezacaftor/ivacaftor therapy was associated with greater CF macrophage CFTR expression and function and corresponding improvements in effector functions. Variable individual donor results and persisting deficits in phagocytic functions suggest the need for continued interventions to improve innate immune function in CF even in the setting of highly effective modulator therapy.

People who are at higher risk for severe illness

Resolvin D1 reduces lung infection and inflammation activating resolution in cystic fibrosis

Resolvins in inflammation: Emergence of the proresolving superfamily of mediators

Nationwide Children's Hospital, Columbus, USA; 2 Center for Microbial Pathogenesis and Division of Pulmonary Medicine, Nationwide Children's Hospital

Nationwide Children's Hospital/The Ohio State University


key: cord-0781098-4pumh9hp
authors: Recchiuti, A.; Patruno, S.; Mattoscio, D.; Isopi, E.; Pomilio, A.; Pecce, R.; Romano, M.
title: 382: SARS-CoV-2 induces distinct inflammatory signals in cystic fibrosis macrophages that are seduced by resolvins
date: 2021-11-30
journal: Journal of Cystic Fibrosis
DOI: 10.1016/s1569-1993(21)01806-3
sha: c31e5ca98d42df9d45c9fa5d9ec490d16302e278
doc_id: 781098
cord_uid: 4pumh9hp

nan

A. Recchiuti 1 , S. Patruno 1 , D. Mattoscio 1 , E. Isopi 1 , A. Pomilio 1 , R. Pecce 1 , M. Romano 1 . 1 Medical, Oral, and Biotechnological Sciences, Università "G. d'Annunzio" Chieti -Pescara, Chieti, Italy Background: In the clinical setting, people with chronic diseases linked to nonresolving inflammation such as cystic fibrosis (CF) are considered at high risk for severe illness from COVID-19 [1] . Resolution of inflammation is an active process in which specialized proresolving lipid mediators such as resolvin (Rv)D1 and RvD2 play pivotal roles in curbing the disproportionate host response while promoting the removal of the noxious stimulus [2, 3] . Therefore, determining pathological responses activated by SARS-CoV-2 in CF and actions of specialized proresolving lipid mediators in SARS-CoV-2induced inflammation are of outmost importance. Methods: Macrophages from volunteers with CF (CF-MΦ) and without CF (non-CF MΦ) were screened for cytokines, chemokines, interferons, growth factors, and microRNAs involved in immune response activated by SARS-CoV-2 spike protein 1 (S1). Bioactivities of RvD1 and RvD2 on these S1triggered cell immune responses and on phagocytosis of Pseudomonas aeruginosa one-way ANOVA or t test were used to compare differences between means (±SE) from each group. Significance was set as P < 0.05. Results: S1 (10 μg/mL, 3 hour) significantly increased the release of chemokines (IL-8, MIP-1α, −1β, MCP-1) by CF MΦ and non-CF MΦ. In contrast, there was a significant increase in IL-6 and TNF-α released by non-CF MΦ but not CF cells and a significantly higher induction of MCP-1 and MIP-1β in non-CF MΦ. IL-8 and MIP-1α steadily increased in a timedependent manner 3 to 24 hours after stimulation with S1 of CF MΦ, whereas they plateaued after 3 hours in non-CF MΦ. TNF-α timedependently increased in CF and non-CF MΦ, whereas IL-6 was enhanced only in non-CF MΦ at 24 hours. Hence, S1 activated a NF-kB-driven, but not interferon-dependent, inflammatory program in CF and non-CF MΦ. After 3 hours of treatment with S1, RvD1 was augmented in CF MΦ, indicating activation of specialized proresolving lipid biosynthetic pathways in these cells but not in non-CF MΦ. RvD1 or RvD2 (10 nM) significantly dampened IL-8, MIP-1α, and TNF-α elicited by S1 in CF and non-CF MΦ by approximately 25% to 50%, whereas they had selective reductive effects on IL-6 in non-CF cells. In CF and non-CF MΦ, RvD1 and RvD2 increased miR-26a and −16 expression, which dampens inflammatory cytokines, whereas miR-223 and miR-125a, which are involved in MΦ activation, were upregulated in a selective manner by RvD1 and RvD2, respectively. RvD1 and RvD2 also enhanced phagocytosis of P. aeruginosa by CF and non-CF MΦ stimulated with S1. Conclusion: These results show the first MΦ responses that are important in COVID-19-related inflammation and resolution, demonstrating that S1 protein has direct, infection-independent, and different proinflammatory actions on CF and non-CF MΦ. The results also foster larger serological and blood cell analyses to assess these differences in CoV-2-positive CF patients and the general population and their impact on clinical manifestations Background: CFTR dysfunction results in multiple abnormalities, including abnormal ion transport and dysregulated host immunity, characterized by poor antimicrobial function and excess inflammation. Macrophages are one such critically altered innate immune cell in CF. Triple combination elexacaftor/tezacaftor/ivacaftor is a new, highly effective CFTR modulator therapy for people with CF (PwCF), with unknown effects on innate immunity. This study aimed to investigate if elexacaftor/tezacaftor/ ivacaftor alters CF macrophage functional responses. Methods: PwCF ( pre-or post-elexacaftor/tezacaftor/ivacaftor treatment) and age-matched non-CF controls were enrolled in a 1-year prospective study. Monocytes were isolated from peripheral blood and analyzed immediately after isolation or differentiated into macrophages (monocytederived macrophages [MDMs]), which were treated with elexacaftor/ tezacaftor/ivacaftor ex vivo (5 mM) 48 hours before experiments. CFTR expression was analyzed by intracellular staining, Western blot, and its distribution was tracked by confocal imaging. CFTR function was measured by halide efflux and whole-cell patch-clamp. Phagocyte function studies were performed using clinical isolates of Burkholderia cenocepacia and Pseudomonas aeruginosa, along with clearance of CFSE-labelled, apoptotic human neutrophils. Interactions were confirmed with scanning or transmission electron microscopy. Results: Elexacaftor/tezacaftor/ivacaftor increased cytosolic and membrane MDM CFTR protein expression, with increased trafficking to the plasma membrane confirmed by confocal microscopy. Increases in CFTR expression corresponded with increased CFTR function as measured by halide efflux and patch-clamp but were variable between individuals and minimal for freshly isolated monocytes. Elexacaftor/tezacaftor/ivacaftor reduced M 2 MDM polarization and antiinflammatory IL-10 production but did not affect proinflammatory cytokine production despite also reducing M 1 polarization. Elexacaftor/tezacaftor/ivacaftor improved neutrophil efferocytosis, bacterial phagocytosis, intracellular reactive oxygen species production, and bacterial killing but did not fully resolve levels of these functions compared to non-CF. Scanning or transmission electron microscopy demonstrated persisting morphologic changes in CF MDMs after elexacaftor/tezacaftor/ivacaftor associated with abnormalities in cytoskeletal genes. Conclusion: Overall, elexacaftor/tezacaftor/ivacaftor therapy was associated with greater CF macrophage CFTR expression and function and corresponding improvements in effector functions. Variable individual donor results and persisting deficits in phagocytic functions suggest the need for continued interventions to improve innate immune function in CF even in the setting of highly effective modulator therapy.

People who are at higher risk for severe illness

Resolvin D1 reduces lung infection and inflammation activating resolution in cystic fibrosis

Resolvins in inflammation: Emergence of the proresolving superfamily of mediators

Nationwide Children's Hospital, Columbus, USA; 2 Center for Microbial Pathogenesis and Division of Pulmonary Medicine, Nationwide Children's Hospital

Nationwide Children's Hospital/The Ohio State University